top of page


Predictive Biomarkers of Thyroid Dysfunctions Associated with the Treatment of Non-Small Cell Lung Cancer and Cervical Cancer with Immune Checkpoint Inhibitors
Ketevan Lomidze,1.2,ID ​Nino Kikodze,2,ID Marine Gordeladze,3 Tinatin Chikovani,2,ID Nino Charkviani3 
Received: 3 May 2023; Accepted: 9 May 2023; Available online: 11 May 2023
Background: Treatment with immune checkpoint inhibitors (ICIs) for advanced malignancies has been associated with developing immune-related adverse events (irAEs) severe enough to require the cessation of life-saving tumor immunotherapy.

Objectives: The present study aimed to identify predictive inflammatory markers of the development of immune-related thyroid dysfunctions in patients with cervical cancer (CC) and non–small cell lung cancer (NSCLC) treated by ICIs.

Methods: A retrospective study was conducted on twenty-seven patients with CC and NSCLC treated by ICIs. The data were collected before and 12 weeks after treatment. Complete blood count-derived inflammatory markers: dNLR (derived neutrophil to lymphocyte ratio), NLR (neutrophil to lymphocyte ratio), SSI (systemic inflammation index), PLR (platelet to lymphocyte ratio), WHR (white blood cells to hemoglobin ratio) were calculated. In addition, thyroid functional tests were collected. Data statistical analysis was performed by STATISTICA (Stat soft, Inc, USA).

Results: Five patients out of twenty-seven with CC treated by PD-1 and CTLA-4 inhibitors who developed hypothyroidism showed significantly high baseline PLR and low WHR compared to patients without clinical symptoms of hypothyroidism and reference levels of TSH and FT4. Association between NLR, dNLR, SSI, and thyroid dysfunction was not observed.

Conclusions: Our findings strongly correlate with hypothyroidism and WHR and PLR biomarkers. As a result, using these biomarkers for early identification of hypothyroidism helps treat thyroid dysfunction and improves cancer immunotherapy outcomes.

Keywords: Hypothyroidism; immune checkpoint inhibitors; inflammatory markers; platelet/lymphocyte ratio; white blood cell/lymphocyte ratio.

DOI: 10.52340/GBMN.2023.01.01.27
Cancer immunotherapy is a promising treatment strategy to improve cancer patients' survival. Novel immunotherapeutic drugs - immune checkpoint inhibitors (ICIs) transfer the immune system from its inhibitory regulatory pathways and upregulate the immune response against tumor cells. (1,2) In clinical practice, the most widely used agents of ICIs' are cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) and PD-1 ligand 1(PD-L1), and ligand 2 (PD-L2) inhibitors.

Unfortunately, even though ICIs have demonstrated a remarkable effect in treating cancer, they gave rise to side effects known as checkpoint toxicities or immune-related adverse events (irAEs). (3,4,5) ICIs have affected almost all organs, but the following systems are more vulnerable: skin, gastrointestinal tract, endocrine system, and joints.

According to the existing evidence, most patients have experienced at least one irAE, and half have experienced at least one grade 3-4 irAE. (6) Although studies report that the development of checkpoint toxicity is associated with better outcomes, some immune-related adverse events are severe enough to require treatment discontinuation and, in rare cases, can lead to death. Thus, early recognition and timely diagnosis are crucial.

Our work addresses thyroid dysfunctions caused by ICI medications. The incidence of immune-related hypothyroidism is significantly higher after treatment with combination therapy (anti-CTLA-4 and anti-PD-1), which is often used for the treatment of cervical cancer (CC) and non–small cell lung cancer (NSCLC). Therefore, predicting the onset of toxicity before therapy is critical for choosing patients for ICIs therapy and personalized monitoring. (3,4)

We aimed to identify the predictive inflammatory markers of developing immune-related thyroid dysfunctions in patients with NSCLC and CC treated with ICIs.
The present retrospective study was conducted in the Israel-Georgian Medical Research Clinic "Healthycore" after the local Ethics Committee approved the study methodology. Immunotherapy-naive NSCLC and CC patients treated with ICIs were included in the study. Patients with thyroid dysfunctions, autoimmune disorders, and recent steroid treatment were excluded from the study.

We collected the data (baseline and 12 weeks after treatment), which contain the following information for each subject: age, sex, gender, tumor stage, TFTs (thyroid functional tests: thyroid stimulating hormone, TSH, and free thyroxine, FT4), and complete blood count-derived inflammatory markers, such as dNLR (derived neutrophil to lymphocyte ratio, absolute neutrophil count/absolute white blood cell count- absolute neutrophil count), NLR (absolute neutrophil count to absolute lymphocyte count ratio), SII (systemic inflammation index, absolute neutrophil count* platelet count/ absolute lymphocyte count), PLR (absolute platelet count to absolute lymphocyte count ratio), WHR (absolute white blood cells to hemoglobin ratio). In addition, according to physical examination signs and symptoms, we calculated "Zulewski's clinical score for hypothyroidism " (
Tab.1). (7) The reference ranges for TSH and FT4 were determined as follows: 0.4-4 µIU/ml and 1-1.8 ng/dL, respectively. 

TABLE 1.  Zulewski’s clinical scoring system
Predictive Biomarkers of Thyroid Dysfunctions Associated with the Treatment of Non-Small Cell Lung Cancer and Cervical Cancer with Immune Checkpoint Inhibitors

* 1 point is assigned when a sign/symptom is present.

Note: A score of 6 and above is defined as hypothyroidism, while 0-2 points are considered euthyroid. A score of 3-5 is defined as intermediate.

For the statistical analysis, we used preliminary descriptive statistics and nonparametric tests. The outcomes were expressed as mean ± standard deviation (M±SD). Finally, to reveal the differences between the two groups, a student’s t-test was used. For all tests, p < 0.05 was considered significant. 
We retrospectively studied the data of sixty patients, but only twenty-seven patients enrolled according to the inclusion and exclusion criteria. NSCLC and CC patients were treated with a PD-1 inhibitor (n=18), PD-1 and CTLA-4 inhibitors in combination (n=6), and PD-1/CTLA-4 inhibitors/chemotherapy (n=3).

Out of 27 patients (10 women and 17 men; median age 61 years), 5 developed immune-related hypothyroidism within 12 weeks. They were all females with cervical cancer treated with a combination of PD-1 and CTLA-4 inhibitors (

TABLE 2. Data of five cervical cancer female patients with immune-related hypothyroidism on PD-1/CTLA-4 inhibitors
Predictive Biomarkers of Thyroid Dysfunctions Associated with the Treatment of Non-Small Cell Lung Cancer and Cervical Cancer with Immune Checkpoint Inhibitors

Abbreviations: FT4, free thyroxine; H, hypothyroidism; PLR, absolute platelet count to absolute lymphocyte count ratio; SH, subclinical hypothyroidism; TSH, thyroid stimulating hormone; WHR, absolute white blood cells to hemoglobin ratio; Z-score, Zulewski’s clinical score for hypothyroidism.

In 12 weeks of treatment, five patients out of 27 revealed a significant increase in TSH (baseline 1.68±0.75, follow-up 66.08±91.46; p<0.0001) and a decrease in FT4 (baseline 1.19±0.15, follow-up 0.68±0.36, p=0.01). In addition, four of the five patients developed severe hypothyroidism, and one had subclinical hypothyroidism. Furthermore, three of the five patients consisted of Zulewski's Clinical score for hypothyroidism. Compared to patients with no clinical signs of hypothyroidism and normal TSH and FT4, all five hypothyroid patients had significantly higher baseline PLR and lower WHR, with p<0.01 and p<0.0001, respectively. No association was found between NLR, dNLR, SSI, and thyroid dysfunction. 
Over the last few decades, a novel tumor immunotherapy strategy, ICI treatment, has emerged. This unique approach involves breaking the immune silence caused by tumors. Checkpoint regulation is more effective than other treatments for many advanced malignancies, although over-activation of the immune system causes adverse effects, and the thyroid gland is periodically engaged. (8)

Complete blood count-derived inflammatory markers have recently been used as prognostic markers in oncology, cardiovascular, autoimmune, and other diseases. (9,10)

In addition, there are several studies where ANC (absolute neutrophil count), NLR, and dNLR have been addressed as the independent predictors of survival in cancer patients, predictive biomarkers of therapeutic response to biologics in autoimmune disease, and predictive role for the risk of preterm delivery, etc. (11,12,13)

As the symptoms of hypothyroidism mimic those of cancer, the diagnosis of thyroid dysfunction may be missed, leading to life-threatening complications. Thus, identifying biomarkers predictive of immune-related endocrinopathies allows physicians to manage patients accordingly. The use of blood cell counts with prognostic value, high clinical significance, and low cost for the early detection of irAEs may be of great interest to clinicians.

According to our results, CC patients who developed hypothyroidism due to ICIs therapy showed high baseline PLR and low WHR. Reports on the association of peripheral blood markers and immune-related adverse events due to ICIs in patients with different cancers are controversial. It was suggested that a higher baseline and increase in absolute lymphocyte counts (ALC) and eosinophil counts (AEC) after ICI treatment were strongly associated with developing irAEs in patients with solid tumors treated with anti-PD-1 antibodies.
(14) A meta-analysis including thousands of patients has shown that a high NLR and PLR at the beginning of ICI therapy was identified as a prognostic marker for developing irAEs. (15,16,17) Our results correspond to the meta-analysis mentioned above: Patients who developed hypothyroidism due to ICIs therapy showed significantly higher PLR than patients who did not have symptoms of irAEs.

Conversely, Leila Khoja et al.'s study revealed that melanoma patients treated with ipilimumab, NLR, PLR, and ELR (eosinophil to lymphocyte ratio) were not associated with toxicity but only with the response to ICI treatment18. We also found no association between NLR and developing hypothyroidism after treatment. It has recently been reported that low NLR at baseline is a risk factor for developing irAEs. Multivariate analysis revealed that NLR <2.86 could be an independent predictive factor for the occurrence of irAEs.
(3,19,20) In other studies, unlike our results, low pretreatment PLR value was significantly associated with the development of irAEs. (3,19) All these results require further validation in additional studies.

The present study has several limitations, such as no data on Anti-TPO (Thyroid peroxidase antibodies), Anti-Tg (Thyroglobulin antibodies) before and after the treatment with ICIs, low numbers of patients, and retrospective design.

Our findings demonstrate a strong correlation between hypothyroidism and WHR and PLR. As a result, using these biomarkers for early diagnosis of hypothyroidism will help to treat thyroid dysfunction and improve cancer immunotherapy outcomes.


Ltd Israel-Georgia Medical Research Clinic “Healthycore,” Tbilisi, Georgia

Department of Immunology, Tbilisi State Medical University, Tbilisi, Georgia

Department of Endocrinology, Tbilisi State Medical University, Tbilisi, Georgia

  1. Geoffrey Alan Watson, Jeffrey Doi, Aaron Richard Hansen, Anna Spreafico Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift? BJCP 2020, Volume86, Issue9.

  2. Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad, Amin Kashani, Seyed reza Hosseini fard, Shadi Hosseini, Habib Sadeghirad, Rahul Ladwa, Ken O’Byrne, Ken O’Byrne Immune Checkpoint Inhibitors in Cancer Therapy Curr. Oncol. 2022, 29(5), 3044-3060;

  3. Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso, Ilaria Attili, Paola Del Bianco, Giulia Pasello, Valentina Guarneri, Giuseppe Aprile, PierFranco Conte, Laura Bonanno Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors Oncologist 2019 Aug;24(8):1128-1136. doi: 10.1634/theoncologist.2018-0563

  4. Conroy, M., & Naidoo, J. (2022). Immune-related adverse events and the balancing act of immunotherapy. Nature Communications, 13(1), 1-4.

  5. Karen M. Yun, Lyudmila Bazhenova, Management of Toxicities Associated with Immune Checkpoint Inhibitors Clinical Advances in Hematology & Oncology March 2023 - Volume 21, Issue 3

  6. Ying Zhang, Xiaoling Zhang, Weiling Li, Yunyi Du, Wenqing Hu, and Jun Zhao Biomarkers and risk factors for the early prediction of immune-related adverse events: a review Hum Vaccin Immunother. 2022; 18(1): 2018894. doi: 10.1080/21645515.2021.2018894

  7. Henryk Zulewski, Beat Müller, Pascale Exer, André R. Miserez, Jean-Jacques Staub, Estimation of Tissue Hypothyroidism by a New Clinical Score: Evaluation of Patients with Various Grades of Hypothyroidism and Controls, The Journal of Clinical Endocrinology & Metabolism, Volume 82, Issue 3, 1 March 1997, Pages 771–776,

  8. Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur Thyroid-related adverse events induced by immune checkpoint inhibitors Front Endocrinol (Lausanne) 2022 Sep 20;13:1010279. DOI: 10.3389/fendo.2022.1010279

  9. Leopoldo Fernández Domper, José A Paramo, Leopoldo Fernández Alonso, Jose Maria Martin Hernández, Maria Morales Suarez-Varela Neutrophil-to-lymphocyte ratio as a cardiovascular risk biomarker in psoriasis: A comprehensive review JEADV clinical practice First published: 21 October 2022

  10. Ancuta Mihai, Ana Caruntu, Daniela Opris-Belinski, Ciprian Jurcut, Alina Dima, Constantin Caruntu, and Ruxandra Ionescu The Predictive Role of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Monocytes-to-Lymphocyte Ratio (MLR) and Gammaglobulins for the Development of Cutaneous Vasculitis Lesions in Primary Sjögren’s Syndrome J Clin Med. 2022 Oct; 11(19): 5525. doi: 10.3390/jcm11195525

  11. Lin Wang, Jing Jia, Lu Lin, Junying Guo, Xingming Ye, Xiongwei Zheng, and Ying Chen Predictive value of hematological markers of systemic inflammation for managing cervical cancerOncotarget. 2017 Jul 4; 8(27): 44824–44832. doi: 10.18632/oncotarget.14827

  12. Xiaoxia Lao, Liping Ma, Qingwei Ma, Qiaorong Ma, Zhige Yang, Lingxiao Guo, Wenzheng Nong Hematological factors associated with immunity, inflammation, and metabolism in patients with systemic lupus erythematosus: Data from a Zhuang cohort in Southwest China Journal of Clinical Laboratory Analysis Volume34, Issue6 June 2020 e23211

  13. Ingrid Hrubaru, Andrei Motoc, Marius Liviu Moise, Bogdan Miutescu, Ioana Mihaela Citu, Raja Akshay Pingilati, Daniela-Eugenia Popescu, Catalin Dumitru, Florin Gorun, Flavius Olaru, Izabella Erdelean, Marius Forga, Nicoleta Nicolae, Cosmin Citu the Predictive Role of Maternal Biological Markers and Inflammatory Scores NLR, PLR, MLR, SII, and SIRI for the Risk of Preterm Delivery J Clin Med 2022 Nov 26;11(23):6982. doi: 10.3390/jcm11236982

  14. Xiao-Hui Jia, Lu-Ying Geng, Pan-Pan Jiang, Hong Xu, Ke-Jun Nan, Yu Yao, Li-Li Jiang, Hong Sun, Tian-Jie Qin, and Hui Guo The biomarkers related to immune-related adverse events caused by immune checkpoint inhibitors J Exp Clin Cancer Res. 2020; 39: 284. doi: 10.1186/s13046-020-01749-x

  15. Saeka Egami, Hitoshi Kawazoe, Hironobu Hashimoto, Ryuji Uozumi, Toko Arami, Naomi Sakiyama, Yuichiro Ohe, Hideo Nakada, Tohru Aomori, Shinnosuke Ikemura, Koichi Fukunaga, Masakaz Yamaguchi, and Tomonori Nakamura Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study J Cancer. 2021; 12(7): 2105–2112. doi: 10.7150/jca.53242

  16. E Suazo-Zepeda, M Bokern , P C Vinke , T J N Hiltermann , G H de Bock , G Sidorenkov

  17. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis 2021 Nov;70(11):3069-3080. doi: 10.1007/s00262-021-02996-3

  18. Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero , Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors  Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events Cancers (Basel) 2023 Mar 6;15(5):1629. DOI: 10.3390/cancers15051629

  19. Khoja L, Atenafu EG, Templeton A, Qye Y, Chappell MA, Saibil S, et al. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Cancer Med. 2016;5(10):2792–9

  20. Wenhui Liu, Yiping Liu, Fang Ma, Bao Sun, Ying Wang, Jianquan Luo, Mouze Liu, Zhiying Luo Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors Cancer Manag Res 2021 Jan 27;13:765-771. doi: 10.2147/CMAR.S293200

  21. Airi Fujimoto, Gouji Toyokawa, Yoshimichi Koutake, Shigeru Kimura, Yosei Kawamata, Kazuhisa Fukuishi, Koji Yamazaki, Sadanori Takeo Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse.

bottom of page